-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2817 Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Program: Oral and Poster Abstracts
Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, ALL, Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinical Research, Diseases, Treatment Considerations, Biological therapies, Real-world evidence, Lymphoid Malignancies
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Xiaopei Lily Zeng, MD1,2, Soyang Kwon, PhD2,3*, Anant Vatsayan, MBBS4, Christina Baggott, PhD5*, Snehit Prabhu, PhD6*, Samuel John, MD7*, Holly L. Pacenta, MD8*, Christine L. Phillips, MD9,10, Jenna Rossoff, MD1,2, Julie-An Talano, MD11, Amy Moskop, MD11, Michael R Verneris, MD12, Douglas D. Myers, MD13*, Erin Marie Hall, MD13*, Nicole A Karras, MD14*, Challice L. Bonifant, MD, PhD15, Muna Qayed, MD16,17, Michelle L. Hermiston, MD, PhD18, Prakash Satwani, MD, MBBS19, Christa Krupski, DO, MPH10,20*, Amy K Keating, MD21,22,23*, Susanne H.C. Baumeister, MD21,22,23, Vanessa A. Fabrizio, MD12, Vasant Chinnabhandar, MD, MBBS24*, Emily Egeler6*, Sharon Mavroukakis, MS6*, Khanh Nguyen6*, Kevin J. Curran, MD25,26*, Crystal L. Mackall, MD5,6,27, Theodore W. Laetsch, MD28,29*, Liora Michal Schultz, M.D.5 and Kevin O. McNerney, MD, MSc1,2

1Division of Hematology, Oncology, Neuro-oncology, and Stem Cell Transplant, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
2Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL
3Stanley Manne Children's Research Institute, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
4Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC
5Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
6Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
7Department of Pediatrics, Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX
8Cook Children's Hospital, Fort Worth, TX
9Cancer and Blood Diseases Institute, Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
10Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
11Department of Pediatrics, Division of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI
12Department of Pediatrics, Division of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado School of Medicine and Children's Hospital of Colorado, Aurora, CO
13Department of Hematology, Oncology and Blood and Marrow Transplantation, Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO
14Department of Pediatrics, City of Hope National Medical Center, Duarte, CA
15Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
16Emory University, Winship Cancer Institute, Atlanta, GA
17Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
18Department of Pediatric, Division of Pediatric Hematology-Oncology, University of California San Francisco, Benioff Children’s Hospital, San Francisco, CA
19Department of Pediatrics, Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Columbia University Medical Center, New York, NY
20Cancer and Blood Disease Institute, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
21Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA
22Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
23Department of Pediatrics, Harvard Medical School, Boston, MA
24Department of Pediatric Oncology, Hematology, Blood and Marrow Transplantation, Perth Children's Hospital, Nedlands, Australia
25Department of Pediatrics, Weill Cornell Medical College, New York, NY
26Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
27Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA
28Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
29Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Purpose:

Relapse is a fundamental challenge following tisagenlecleucel (CD19 CAR T cells; tisa-cel) in children and young adults (CAYA) with relapsed/refractory B-acute lymphoblastic leukemia (B-ALL). B cell aplasia (BCA) is a surrogate marker of tisa-cel persistence, and early B cell recovery (BCR <6 months) has been associated with an increased risk of relapse on Phase I-II clinical trials. The impact of late BCR (≥ 6 months) on relapse is less well defined, and the impact of early and late BCR on relapse risk and relapse immunophenotype with real-world data is not known.

Methods:

This multi-institutional retrospective study of CAYA infused with commercial tisa-cel included patients from Pediatric Real World CAR Consortium (PRWCC) centers (N=207), treated between 2017 and 2024. BCR was defined as return of normal CD19-positive (CD19+) B cells in the peripheral blood or bone marrow hematogones, with thresholds determined by institution. Loss of BCA was defined as the first occurrence of any CD19+ event (BCR or CD19+ relapse). Duration of BCA was defined as days from infusion without loss of BCA, censored for additional leukemia-directed therapy and CD19-negative (CD19-) or CD19 unknown relapse, with median duration of BCA determined by the Kaplan-Meier (KM) method. Cumulative incidence functions were separately performed for loss of BCA and CD19+ relapse, considering CD19- or CD19 unknown relapse and therapy in remission as competing events. Relapse-free survival (RFS) analyses via KM were performed for overall, CD19+, and CD19- relapses separately, censoring for therapy in remission and non-relapse death. Landmark analyses for RFS at landmark times of day + 90, 180, 270, and 365 days were performed, comparing groups with and without BCR by each landmark time. BCR was evaluated as a time-varying covariate (TVC) for CD19+ and CD19- relapse in a Cox proportional hazard model. Therapy for BCR while in remission, defined as tisa-cel re-infusion, alternative CAR T product, HSCT, or other cancer-directed therapy, was evaluated as a TVC for subsequent relapse. Event-free survival (EFS) was evaluated using the extended KM method in those who received versus did not receive treatment for BCR including death and relapse as events.

Results:

Of 207 patients, 178 (86%) had a complete response at 1-month with 94% of responders achieving flow MRD-negative status. The 1- and 2-year RFS in responders were 62% and 53%. Cumulative incidence of any relapse at 2 years was 45% (21% CD19+, 20% CD19-, and 4% CD19 unknown). Among 156 responders with reported B cell assessments, 75 experienced loss of BCA (including 9 who had CD19+ relapse without documented BCR) with median BCA duration of 262 days (95% CI 174, NA) with censoring and 396 days (95% CI 192, NA) without censoring for non-CD19+ relapse or further therapy. Cumulative incidence of loss of BCA at day 90, day 180, 1 year, and 2 years 22%, 38%, 45%, and 50% respectively. Of the 66 patients who experienced BCR, 80% (N=53) occurred early (<180 days) and 83% (N=55) occurred before day of relapse. In landmark analyses, CD19+ RFS was significantly worse for those with BCR prior to landmarks of day 90, 180, 270, and 365, compared to those without BCR by each timepoint (p<0.001 for all). No significant differences in CD19- RFS were observed across landmark times. Similarly, when evaluated as a TVC, BCR within 1 year of infusion increased risk of CD19+ relapse (HR 6.34; 95% CI 2.79, 14.45; p<0.001), but not CD19-relapse (HR 0.83; 0.20-3.68; p=0.80). Therapy given in remission for BCR, evaluated as a TVC, was associated with lower risk of CD19+ relapse [HR 0.27; 95% CI 0.10, 0.73, p=0.01] and significantly improved EFS compared to those who did not receive therapy (median EFS not reached vs. 181 days from BCR, p=0.007).

Conclusion:

In the real-world commercial tisa-cel setting, we show a relatively shorter duration of BCA when compared with the ELIANA trial, where the median time to BCR was 35.3 months from the time of remission. Our work confirms the prognostic significance of B cell recovery for CD19+ but not CD19- relapse and suggests BCR between 6 months to 1 year post-infusion continues to be associated with a risk of CD19+ relapse. Finally, we show that leukemia-directed therapy after BCR was associated with lower risk of CD19+ relapse and improved EFS. The continued risk of CD19+ relapse for patients with BCR between 6 months to 1 year raises questions of optimal management of BCR in this window.

Disclosures: Phillips: Novartis: Membership on an entity's Board of Directors or advisory committees. Myers: Novartis Pharmaceuticals: Consultancy. Hermiston: Sobi: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Fabrizio: Adaptimmune: Consultancy. Mackall: Adaptimmune: Consultancy; Link Cell Therapies: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Bristol Meyers Squibb: Consultancy; Mammoth: Consultancy, Current equity holder in private company; Ensoma: Consultancy; Immatics: Consultancy; Lyell Immunopharma: Current equity holder in publicly-traded company, Research Funding; Cargo Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees. Laetsch: Advanced Microbubbles: Consultancy, Membership on an entity's Board of Directors or advisory committees; AI Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; ITM Oncologics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; Eli Lilly: Research Funding; Exelixis: Research Funding.

*signifies non-member of ASH